Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for ...

It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

The top U.S. Food and Drug Administration official on Tuesday confirmed AstraZeneca Plc's U.S. COVID-19 vaccine trial is on ...

About 1 in 4 American adults got a covid vaccine shot during the 2024-25 virus season, a fraction health care experts warn could be smaller this year as millions wrestle with conflicting advice from ...

The inequitable distribution of vaccines during the COVID-19 pandemic was the final proof of the need for more home-grown ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

SHUTDOWN’S END — The Senate overcame a key procedural hurdle Sunday to set up a vote Monday on a House bill to fund the ...

A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.